SS
OBIO icon

Steve Schonfeld’s Orchestra BioMed OBIO Stock Holding History

Steve Schonfeld’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,953
Closed -$46.5K – 2884
2026
Q1 		$46.5K Buy
+10,953
New +$46.6K ﹤0.01% 1980
2022
Q3 		– Sell
-42,998
Closed -$428K – 3103
2022
Q2 		$428K Buy
+42,998
New +$427K ﹤0.01% 1449

Other funds holding OBIO

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Steve Schonfeld's OBIO Position: Q2 2026 in Review

Steve Schonfeld sold out of Orchestra BioMed (OBIO) in Q2 2026, closing a stake of 10,953 shares — an estimated $46.5K sold.

Steve Schonfeld first reported a position in OBIO in Q2 2022 and held it in 2 quarters. The position peaked at $428K in Q2 2022. 76 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

  • Steve Schonfeld reported no remaining Orchestra BioMed position as of Q2 2026 after selling out during the quarter.
  • Steve Schonfeld sold 10,953 Orchestra BioMed shares in Q2 2026, an estimated $46.5K.
  • Steve Schonfeld first reported a position in Orchestra BioMed in Q2 2022 and held it in 2 quarters.
  • Steve Schonfeld's Orchestra BioMed position peaked at $428K in Q2 2022.
  • 76 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.